Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Kinnate Biopharma stock (Kinnate Biopharma)

Buy Kinnate Biopharma stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Kinnate Biopharma is a biotechnology business based in the US. Kinnate Biopharma shares (KNTE) are listed on the NASDAQ and all prices are listed in US Dollars. Kinnate Biopharma employs 84 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Kinnate Biopharma Inc stock

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Top pick for best mobile experience

Go to site
  • Trade $0 commission stocks, ETFs, and options with as little as $1
  • After-hours trading available
  • Earn 4.5% interest on uninvested cash with Gold
  • 24/7 customer support

Alternative pick for crypto trading

Go to site
  • $0 commission trading
  • Instant withdrawals with a 1.75% fee
  • Supports 250+ cryptocurrencies
  • High-yield account earns up to 4.65% APY
Terms apply. Cryptoassets are highly volatile. Your capital is at risk. Available in the US, CA, UK and AU

Disclaimer: This page is not financial advice or an endorsement of digital assets, providers or services. Digital assets are volatile and risky, and past performance is no guarantee of future results. Potential regulations or policies can affect their availability and services provided. Talk with a financial professional before making a decision. Finder or the author may own cryptocurrency discussed on this page.

How to buy Kinnate Biopharma stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – KNTE. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Kinnate Biopharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
Uphold
Finder Score: 3.6 / 5: ★★★★★
Uphold
★★★★★
Cryptocurrency
N/A
$0
4.65%
Get $10
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Kinnate Biopharma stock price (NASDAQ: KNTE)

Use our graph to track the performance of KNTE stocks over time.

Kinnate Biopharma shares at a glance

Information last updated 2024-06-30.
52-week range$2.14 - $2.69
50-day moving average $2.49
200-day moving average $2.24
Wall St. target price$2.36
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-2.78

Is it a good time to buy Kinnate Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kinnate Biopharma financials

Gross profit TTM $0
Return on assets TTM -33.63%
Return on equity TTM -55.8%
Profit margin 0%
Book value $3.66
Market Capitalization $125 million

TTM: trailing 12 months

Kinnate Biopharma share dividends

We're not expecting Kinnate Biopharma to pay a dividend over the next 12 months.

You may also wish to consider:

Kinnate Biopharma share price volatility

Over the last 12 months, Kinnate Biopharma's shares have ranged in value from as little as $2.14 up to $2.69. A popular way to gauge a stock's volatility is its "beta".

KNTE.US volatility(beta: 1.34)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kinnate Biopharma's is 1.34. This would suggest that Kinnate Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Kinnate Biopharma's beta into context you can compare it against those of similar companies.

Kinnate Biopharma overview

Kinnate Biopharma Inc. , a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC. .

Frequently asked questions

What percentage of Kinnate Biopharma is owned by insiders or institutions?
Currently 0.157% of Kinnate Biopharma shares are held by insiders and 82.583% by institutions.
How many people work for Kinnate Biopharma?
Latest data suggests 84 work at Kinnate Biopharma.
When does the fiscal year end for Kinnate Biopharma?
Kinnate Biopharma's fiscal year ends in December.
Where is Kinnate Biopharma based?
Kinnate Biopharma's address is: 103 Montgomery Street, San Francisco, CA, United States, 94129
What is Kinnate Biopharma's ISIN number?
Kinnate Biopharma's international securities identification number is: US49705R1059

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site